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Abstract
Background: Plasmodium berghei rodent malaria is a well-known model for the investigation of anti-malarial drug
efficacy in vivo. However, the availability of drug in vitro assays in P. berghei is reduced when compared with the
spectrum of techniques existing for Plasmodium falciparum. New alternatives to the current manual or automated
methods described for P. berghei are attractive. The present study reports a new ELISA drug in vitro assay for P. berghei
using two monoclonal antibodies against the parasite lactate dehydrogenase (pLDH).
Methods: This procedure includes a short-in vitro culture, the purification of schizonts and the further generation of
synchronized mice infections. Early stages of the parasite are then incubated against different concentrations of
anti-malarial drugs using micro-plates. The novelty of this procedure in P. berghei relies on the quantification of the drug
activity derived from the amount of pLDH estimated by an ELISA assay using two monoclonal antibodies: 14C1 and
19G7. The IC50s obtained through the ELISA assay were compared with those from the micro-test.
Results: The initial parameters of the synchronized samples used in the in vitro assays were a parasitaemia of 0.5% and
haematocrit of 1%, with an incubation period of 22 hours at 36.5°C. pLDH detection using a 14C1 coating at 10 μg/ml
and 19G7 at 2.5 × 10-3 μg/ml provided good readouts of optical densities with low background in negative controls and
specific detection levels for all parasite stages. IC50s values derived from the ELISA assay for artesunate, chloroquine,
amodiaquine and quinine were: 15, 7, 2, and 144 nM, respectively. When artesunate and chloroquine IC50s were
evaluated using the micro-test similar values were obtained.
Conclusion: This ELISA-based in vitro drug assay is easy to implement, fast, and avoids the use radioisotopes or
expensive equipment. The utility of this simple assay for screening anti-malarial drug activity against P. berghei in vitro is
demonstrated.
Keywords: Plasmodium berghei, In vitro culture, schizont, synchronized infection, drug in vitro assay, anti-malarials, IC50
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Background
Murine malaria models have contributed to the under-
standing of the biology and pathology of human malarias.
Although the immune system and drug pharmacokinet-
ics between humans and rodents may be different, the
drug sensitivity profile between these Plasmodium spe-
cies is mostly shared. Drug efficacy studies in small
rodents have been mainly performed in vivo using
different strains of Plasmodium berghei and the classical
four-day suppressive test [1]. The use and development
of in vitro techniques for anti-malarial drug-screening in
P. berghei has been less prominent, especially when
compared with the variety of in vitro assays described
for Plasmodium falciparum. In vitro assays are comple-
mentary to in vivo tests, and in P. berghei some advan-
tages of the in vitro assays include: i) the measurement
of intrinsic anti-malarial activity, excluding confounding
factors from the host such as the immune system; ii)
the evaluation of larger number of compounds in one
experiment with possible prediction of an in vivo
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outcome, and iii) the identification of discrepancies in
the sensitivity profiles of P. berghei and P. falciparum.
Different drug in vitro assays have been adapted and
developed for P. berghei. These assays include: the WHO
schizont maturation test (micro-test) [2], the radioiso-
topic assay [3] and the measurement of parasite nucleic
acids using fluorescent dyes and flow cytometry [4,5].
More recently, a luminescence assay using a transgenic
line of P. berghei expressing luciferase was also developed
[6]. These techniques can be limited by labour-intensive
steps, disposal of radioactive waste and high costs.
Early studies of the metabolic pathways of Plasmo-
dium led to the identification of enzymes structurally
different from the host, such as lactate dehydrogenase
(LDH) [7]. Plasmodium parasites require intense LDH
activity to ensure the high metabolism of carbohydrates
during the complex intraerythrocytic cycle [8]. These
singularities pointed to parasite LDH (pLDH) detection
as a good target for the development of colorimetric [9]
and ELISA [10] based drug in vitro assays for P. falcip-
arum. The aim of this study was to develop an in vitro
enzyme-linked immunosorbent drug assay for P. berghei,
using two monoclonal antibodies against pLDH and the
semi-automated micro-dilution technique [11]. This
in vitro susceptibility test starts with P. berghei mouse
infections followed by a short in vitro culture and a
synchronization procedure to generate the P. berghei
samples to be evaluated in the drug in vitro assays. The
measurement of drug activity is derived from the relative
amount of P. berghei LDH (estimated by ELISA) as a
function of the drug concentration.
Methods
Short-term parasite in vitro culture and synchronization
13-week old C57BL/6 (The Jackson Laboratory,
Sacramento, CA) mice were infected intraperitoneally (IP)
with 1 × 103 P. berghei ANKA (PbA) or P. berghei ANKA
expressing GFP (PbAGFP) [12] (a donation from the
Malaria Research and Reference Reagent Resource Center
(MR4), Manassas, VA; deposited by MF Wiser and M
Hollingdale and CJ Janse and AP Waters, respectively;
MR4 number: MRA-671 and MRA-865). At a parasi-
taemia of 2 - 3%, mice were anesthetized (ketamine, 150
mg/kg and xylazine, 10 mg/kg) and 0.5 ml of blood was
collected by retro-orbital puncture, after which mice were
euthanized by an IP injection of Euthasol (100mg/kg). Ani-
mal handling and care followed the NIH Guide for Care
and Use of Laboratory Animals. All protocols were
approved by the La Jolla Bioengineering Institutional Ani-
mal Care and Use Committee.
Infected heparinized blood samples were washed twice
in phosphate-buffered saline (PBS) solution and cultured
in media RPMI 1640 (Gibco, Life Technologies) supple-
mented with 20% inactivated fetal bovine serum
(complete RMPI) following the procedures described by
Janse and Waters [13]. Cultures were flushed with a
standard gas mixture of 5% O2, 5% CO2, 90% N2 and
incubated for 22 hours at 36.5°C. Purification of fully
mature schizonts from uninfected red blood cells or
younger parasites’ stages was performed following the
protocol described by Janse et al. [14] with some modifi-
cations. Briefly, 25 ml of the overnight parasite culture
was transferred to a 50 ml falcon tube (Becton, Dickinson)
and 8 ml of 55% Nycodenz (v/v, PBS) was added to the
bottom of the tube. Tubes were centrifuged at 450 g in
a swing-out rotor for 30 minutes without brake. After
centrifugation, the visible suspended brown ring contai-
ning mostly mature schizonts was carefully collected into
another falcon tube. Schizonts were washed in complete
RPMI media, resuspended in 100 μl of PBS and injected
intravenously (IV) into the pre-warmed tails of 13-week
old C57BL/6 mice. Between 48 to 72 hours post-infection,
an optimal synchronized parasitaemia of 1 to 3% was
reached. Mice were anesthetized as previously described
and parasite blood samples were collected. To adjust
the parasitaemia and haematocrit for the in vitro assay
samples, a pool of blood from uninfected mice was also
gathered.
Mice parasitaemia and synchronized infections of
P. berghei were analysed by flow cytometry and
Hemacolor (Merck) stained thin blood smears. Tail
blood samples from infected and uninfected mice were
diluted 100-times in PBS, and subsequently acquired in
a FACSCalibur cytometer (Becton Dickinson). Samples
were excited using a 488 nm argon laser and GFP emis-
sion was detected with a 530/30 nm band pass filter.
FCS Express (De novo Software) was used for all flow
cytometry analyses by first gating for intact erythro-
cytes by side scatter and forward scatter parameters,
and subsequently determining the proportion of GFP
positive cells. The fluorescence intensity and the
forward-scattered light of at least 10,000 cells per sam-
ple were measured. A negative control sample from an
uninfected mouse was tested in parallel to define the
threshold of positivity for the parasitaemia.
Drug in vitro assays
The anti-malarial drugs evaluated in the in vitro assays
were: chloroquine diphosphate salt, amodiaquine dihy-
drochloride dihydrate, quinine hydrochloride dihydrate
and artesunate (all from Sigma-Aldrich). The drugs were
diluted in ethanol 70% (v/v, ultrapure water) with the ex-
ception of chloroquine that was diluted in ultrapure
water. The stock solutions of each drug were used to
prepare two-fold dilution series in complete RPMI
medium. The dilutions ranging from: 3.8-240 nM
chloroquine, 1–65 nM amodiaquine, 50–3150 nM
quinine-HCL and 0.6-40 nM artesunate were distributed
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(25 μl per well) in 96-well plates (Corning, Life Science)
where the drug in vitro assays were performed.
Uninfected and infected red blood cells containing pri-
marily early trophozoites were washed twice in PBS prior
to use in the in vitro assays. Infected red blood cells were
diluted in complete RPMI medium to a final parasitaemia
of 0.5% and 1% of haematocrit and dispensed (225 μl per
well) into the pre-dose drug plates. In each experiment,
wells with uninfected and infected red blood cells without
drug were included as negative and positive controls of
growth, respectively. In addition, aliquots from the positive
controls were frozen immediately in order to assess pLDH
activity at time zero of incubation. The drug in vitro plates
were incubated in gas atmosphere of 5% CO2, 5% O2, and
90% N2 at 36.5°C for 22 to 24 hours. At the end of the in-
cubation period, thin blood smears of positive controls
were performed to confirm the presence of mature schi-
zonts (with 8 to 16 merozoites).
The drug concentrations that inhibited 50% of parasite
growth (measured by optical densities – ODs in the
ELISA assays) compared to the control samples without
drug (IC50s) were calculated using HN-NonLin [15].
Drug-response curves were plotted in GraphPad Prism.
Data were expressed as mean ± standard deviation (SD),
unless otherwise indicated.
Enzyme-linked immunosorbent assay
Monoclonal antibodies 14C1 (a kind donation of Dr.
Michael Makler) and 19G7 (purchased from Flow Inc.,
Portland, OR) developed for pLDH-based malaria diag-
nostic tests [16] were used as capture and detection
antibodies, respectively (these monoclonal antibodies
are now owned by AccessBio, Somerset, NJ). Biotinyla-
tion of 19G7 (10 μg/ml) was carried out using the EZ-
Link Sulfo-NHS-LC-Biotinylation Kit (Pierce Biotech-
nology) following the standard protocols provided by
the manufacturer. The 2-(4-hydroxyazobenzene) ben-
zoic acid (HABA) assay also included in the EZ-Link
Sulfo-NHS-LC-Biotinylation Kit was used for measur-
ing the level of biotin incorporation per immunoglobu-
lin molecule.
The ELISA technique described above was standar-
dized from the DELI assay developed for P. falciparum
with modifications [10]. Nunc MaxiSorp flat-bottom 96
well plates (Gibco) were coated with 100 μl of capture
antibody 14C1 (10 μg/ml) and incubated at 4°C for 24
hours. Plates were washed with phosphate-buffered sa-
line (PBS) 0.025% (v/v) Tween 20 (PBS/Tween) and
blocked with 1% (w/v) Bovine Serum Albumin Fraction
V (Roche) (PBS/BSA). After 24 hours of incubation at 4°C,
the plates were washed, covered with plastic seals, refrige-
rated and used within a month.
Once the drug in vitro assays were performed, the plates
were frozen/thawed three-times and the haemolyzed
samples were homogenized. 100 μl of haemolyzed samples,
undiluted and diluted (1:10, 1:50 and 1:100 in PBS), was
transferred into the coated ELISA plates and incubated for
1 hour at 37°C. The plates were washed and 100 μl of a
1:4,000 dilution (2.5 × 10-3 μg/ml) of 19G7 biotinylated
antibody was added. After 1 hour of incubation at 37°C,
plates were washed and incubated for 30 minutes with
100 μl of a 1:10,000 dilution (0.125 μg/ml) of peroxidase-
conjugated streptavidin preparation (1.25 mg/ml) (Pierce
Biotechnology). After the last wash, 100 μl of TMB
(3,3´,5,5´-tetramentylbenzidine) (1-Step Ultra TMB-ELISA,
Thermo Scientific) was added to the plate and incubated
for 20 minutes at room temperature. The reaction was
stopped by adding 100 μl of 2 M H2SO4 solution, and read
at 450 nm in a μQuant micro-plate spectrophotometer
(Bio-Tek Instruments).
Results and discussion
Initial ELISA assays aimed to evaluate the antibody rec-
ognition capability of PbAGFP samples and establish the
optimal antibody concentrations to be used. ELISA
assays were first conducted in uncultured and asyn-
chronous parasites adjusted to 1% and 2.5% of parasit-
aemia and haematocrit, respectively. Initial coating
plates concentrations (10, 50 and 100 μg/ml) of primary
antibody (14C1) versus the secondary antibody (19G7)
(1:1,000 [0.01 μg/ml] to 1:64,000 [1.56 × 10-4 μg/ml]
two-fold dilution) were tested. These preliminary experi-
ments showed that independently from the coating con-
centration used, dilutions of the secondary antibody
below 1:6,000 (1.67 × 10-3 μg/ml) did not significantly
differ in their antigen detection capability. Using a con-
centration of 10 μg/ml of 14C1 and a 1:4,000 dilution
(2.5 × 10-3 μg/ml) of 19G7, the assay generated absorb-
ance values of 2.7 (± 0.01) for infected samples and 1.2
(± 0.01) for negative controls: uninfected blood and
complete RPMI media. Based on these preliminary
results, next assays attempted to reduce the high absorb-
ance values obtained for the negative controls. Simple
modifications were performed: (i) reduced the haemato-
crit of the samples to 1%, (ii) supplemented the PBS
used for washes with Tween-20 0.05%, (iii) and per-
formed and extra wash at all ELISA steps (four in total).
These basic protocol changes significantly reduced the
absorbance from the negative controls from 1.2 (± 0.01)
to 0.2 (± 0.02) whereas the infected samples still showed
good detection levels (1.5 ± 0.3).
Parasite blood samples used in these preliminary tests
were uncultured and asynchronous with different stages
of the parasite producing different levels of pLDH. Since
the in vitro drug method proposed here is based on the
schizont maturation inhibition assay [2], next experi-
ments were directed to evaluate the ELISA standardized
conditions in late stages of PbAGFP. The P. berghei life
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cycle takes approximately 24 hours and under static
in vitro culture conditions the asynchronous parasites
from the mice infection develop into mature schizonts
that do not burst in culture. Two different parasitaemias
(0.5% and 1%) of cultured mature schizonts obtained
after 22 hours of in vitro culture were evaluated in the
ELISA assays. Since the absorbance expected for these
stages was the highest [17], three different dilutions (1:2,
1:10 and 1:50 in PBS) of the samples were tested. The
performance of the ELISAs using a 0.5% or 1% parasit-
aemia showed no critical differences and both worked
well. At 0.5% parasitaemia, culture dilution 1:10 resulted
in absorbance values in the range of 2.2 to 1.3 (1:2,000
[5.0 × 10-3 μg/ml] to 1:6,000 [1.67 × 10-3 μg/ml] secondary
antibody dilution, respectively) (Figure 1). At 1% parasi-
taemia, both 1:2 and 1:10 culture dilutions resulted in
high absorbance values (between 4.0 and 2.6, except at
1:6,000 secondary antibody dilution, absorbance = 1.8).
Signal-to-noise ratios at culture dilution 1:50 were not
as good as dilution 1:10. It was concluded therefore that
in cultures with 0.5% parasitaemia diluted 1:10, any of
these 19G7 dilutions were appropriate. Dilution 1:4,000
(2.5 × 10-3 μg/ml) of 19G7 was selected for further use in
this study as it provided a better signal-to-noise ratio
than 1:6,000, and allowed using lower amount of secon-
dary antibody than dilution 1:2,000. For cultures at 1%
parasitaemia, the combination of 1:10 culture dilution
with 19G7 dilution 1:6,000 would be appropriate as well.
The use of different combinations does not seem to be
critical for the assay, as long as the absorbance values
fall within the non-saturation (non-plateau) range. As
can be seen in Figure 1, the plateau is far from being
reached at 1:10 dilutions (that is, 1:2 dilutions still pro-
vide absorbance values well above those observed with
1:10 dilutions).
The development of P. berghei in mice is relatively
asynchronous and unsuitable for schizont inhibition
assays, since most of the anti-malarial drugs are parasite
stage-specific. In P. falciparum, synchronization can be
easily performed by sorbitol treatment [18]. However
due to alterations in the permeability of murine erythro-
cytes this procedure is less efficient in P. berghei [19]. A
suitable alternative for P. berghei synchronization is the
development of synchronous infections in mice. Follow-
ing the procedures described by Janse and Waters [13],
synchronized infections of PbA and PbAGFP were gen-
erated and followed by thin blood smears and/or flow
cytometry (Figure 2). PbAGFP express GFP throughout
the whole life cycle and displays different GFP-
fluorescence intensity during each stage [12] facilitating
the analyses of mice synchronized infections by flow
cytometry. As expected, asexual blood stages of PbAGFP
with different parasite stages were found during the
course of the infection (Figure 2, histogram B). Once the
parasites were collected from the mice and cultured
overnight, a highly pure and concentrated population of
mature schizonts was gathered through the use of the
Nycodenz gradients (Figure 2, histogram C). Collected
schizonts (approximately 1 × 107) were then injected IV
into mice and 30 hours post-infection a highly synchro-
nized parasitaemia of 1-3% was observed (Figure 2, his-
tograms D to F). This procedure allowed the acquisition
of the early stage parasite samples required for the con-
duction of the drug in vitro assays. This protocol was
also useful for PbA (wild type, not expressing GFP)
synchronization but parasite development was only fol-
lowed by thin blood smears.
After having standardized the synchronized infections
in mice, the next objective was to confirm the capability
of the ELISA assay to detect pLDH activity throughout
the different stages of the parasite life cycle in samples
that were grown under the in vitro assay conditions. To
do this, parasites from synchronized infections were col-
lected in early stages of development (early trophozoites
adjusted to 1% of haematocrit and 0.5% of parasitaemia)
and short-cultured in 96-well plates. Incubation of plates
was performed at 36.5°C in a desiccator plastic chamber
filled with a sterile gas mixture (5% CO2, 5% O2, and
90% N2). Higher incubation temperatures (37°C and
37.5°C) were also tested but under these conditions
parasites did not develop into mature schizonts and the
presence of degenerated schizonts was common.
Over the 22 hours of the incubation period parasite
samples were collected at different time points in
order to perform thin blood smears and the meas-
urement of pLDH activity. In Figure 3 it can be
observed how pLDH levels increased as the parasite
grew during the incubation time. Ring samples at
time 0 of incubation had an initial OD value of 0.25
Figure 1 Effect of sample dilution in pLDH detection – ELISA
standardization. Vertical bars represent mean optical density (OD)
values ± SD obtained from PbAGFP cultured schizonts at 0.5% or 1
% of parasitaemia and uninfected red blood cells (unRBC) at 1% of
haematocrit. Grey and white bars represent schizonts culture at 1%
and 0.5% of parasitaemia, respectively. Three different concentrations
of 19G7 (secondary antibody) were tested (X-axis). Mean is derived
from three independent assays.
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(± 0.02). After 4 hours of incubation, intracellular
growth occurred, trophozoites predominated in the
culture and the OD nearly doubled to 0.45 (± 0.02).
Ten hours after the second sample was taken (schi-
zonts) the OD reached 1.0 (± 0.06), with a slight in-
crease at 18 hours. The OD remained stable until
the end of the culture (22 hours) when fully mature
schizonts with more than 8 nuclei were observed.
These simple growth tests confirmed that the
short-culture conditions to be used in this in vitro
assay supported well the parasite growth and the
feasibility of this ELISA-based technique to detect it.
These results also show that the maximal pLDH ac-
tivity was generated when the parasites developed
from early trophozoites into schizonts, which is con-
sistent with previous reports in P. falciparum where
the peak of L-lactate (product of pLDH activity)
coincided with the beginning of the schizogony
[17,20]. There was no significantly increase in pLDH
values after 16 hours of incubation when nuclear div-
ision and merozoite formation start to occur. These
findings indicate that this assay is appropriate to
evaluate drugs that affect the parasite’s growth and
maturation but not for drugs targeting DNA synthe-
sis during schizogony. In addition, in the absence of
an efficient long-term continuous culture of P. ber-
ghei [21,22] the drug in vitro assay proposed here is
based on a single cycle. Therefore, this test is not
suitable for the evaluation of drugs that have no ap-
parent effect until division and reinvasion of new red
blood cells by the daughter merozoites occur
(delayed-death phenomenon described with antibac-
terial drugs in P. falciparum) and whose effect can
only be estimated in the next developmental cycles
[23]. For this kind of drugs, other in vitro assays for
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Figure 2 Flow cytometry analyses of synchronized infections of P. berghei in C57BL/6 mice. A) Panel showing uninfected red blood cells
(negative controls). B) Asexual blood-stages of PbAGFP from infected mice with normal day-night light regime. C) Highly fluorescent mature
schizonts purified after 22 hours of in vitro culture used to generate synchronized P. berghei infections in mice. D) Rings, E) trophozoites and F)
schizont-enriched populations from synchronized infections after one cycle of replication in mice. *hpi=hours post-infection.
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schizont-specific expression are available [6]. The re-
cent report of a new in vitro culture technique for P. ber-
ghei that allows reinvasion of normal mouse red blood
cells and continuous culture for over two weeks [24] might
also overcome this limitation.
For the in vitro assays, early parasite stages (rings)
obtained from synchronized infections were used. Para-
sites were incubated with the different concentrations
of the anti-malarial drugs at 36.5°C for 22 hours.
Slides confirming the fully maturation of healthy schi-
zonts in the positive control wells were always per-
formed at the end of each assay. Figure 4 shows the
absorbance recorded for positive and negative controls
during the drug in vitro assays. Absorbance values of
negative controls were 0.14 (± 0.03) and 0.10 (± 0.01)
for uninfected red blood cells and complete RPMI media,
respectively. The negative controls showed significantly
lower absorbance (Fisher Exact Test, p = 0.0001) than
infected samples, regardless of the time of collection.
Infected samples at time zero of growth also showed low
absorbance values (0.3 ± 0.10), as expected for early stages,
but significantly doubled (Fisher Exact Test, p = 0.0001)
the OD values of the negative controls. After 22 hours of
incubation, the samples from time zero of growth tripled
their absorbance values to 1.1 (± 0.2 SD). These results
clearly show the suitability of the antibodies to for P. ber-
ghei detection.
The in vitro response of P. berghei to common
anti-malarial drugs can be observed in Figure 5.
Since no differences between the IC50s values of the
wild type (PbA) and the transgenic line (PbAGFP)
were observed, curves for both parasites were plotted
together. The IC50 of chloroquine and artesunate was
also investigated for PbAGFP using the micro-test [2]
with similar results for both techniques (Figure 5).
The IC50 values for artesunate obtained in this work
(15 nM) are in accordance with previous reports for
this species [5,6]. Janse et al. [5] developed and
in vitro assay for P. berghei analyzing the amount of
parasite DNA through Hoechst staining and flow
cytometry and reported IC50 values for artesunate of
11 nM. More recently, the same group developed an-
other anti-malarial drug screening in vitro assay
using a transgenic line of P. berghei expressing luci-
ferase [6]. Through this highly sensitive technique,
the recorded IC50 values of artesunate ranged from 4 to 26
nM. IC50 values for chloroquine in sensitive P. berghei
strains have also been described through the use of
the different techniques. Early reports of IC50s for
chloroquine sensitive lines (NK65 strain) using the
radioisotopic assay ranged between 155 nM [25] and
230 nM [3]. A report in another murine Plasmodium
Figure 3 Relationship between growth, stage development and
pLDH optical density of synchronized cultures of P. berghei.
Parasites were cultured under drug in vitro assay conditions without
drug. Samples were collected and frozen at the different time
points. Asterisks represent the mean and standard error of two
different experiments. A picture of a mature schizont (usually
containing 8–16 nuclei) collected at the end of the assay (hour 22) is
also shown.
Figure 4 Optical density readings from drug in vitro assay
controls. pLDH OD values for negative controls: complete RMPI
media (cRPMI, N = 9 wells), uninfected red blood cells (unRBCs, N =
45 wells) and positive controls (N = 84 wells): infected red blood
cells without drug collected at time zero of incubation (T0) and after
finished the assay (22h). Wells from different assays were plotted
together and at least three independent assays were performed per
each group. Values are displayed in box plots, means and outliers
are represented by solid crosses and black circles, respectively.
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species Plasmodium chabaudi described an IC50
value of chloroquine of 30 nM using the radioiso-
topic technique [26]. More recently, IC50 values of
30 nM were also described in P. berghei using the
luciferase assay [6]. In the present study, the IC50s
values for chloroquine sensitive lines (PbA and
PbAGFP) were 7 nM and 20 nM using the pLDH
ELISA and the micro-test, respectively (Figure 5);
both values are within the range of IC50 values
described for sensitive chloroquine strains of Plasmo-
dium in rodents [3,6,25,26] and similar to those
reported in P. falciparum [10,27-30] and Plasmodium
vivax [24,31]. The reports of IC50s for amodiaquine
and quinine in P. berghei are more restricted, mainly
derived from the radioisotopic assays: 430 nM and
1500 nM, respectively [3]; another study showed an
IC50 of 210 nM for quinine-HCL using again the
radioisotopic technique [25]. In this work was found
that P. berghei ANKA lines were sensitive to amodia-
quine (IC50 of 2nM) and quinine (IC50 of 144 nM).
These values have been also described in sensitive
strains of P. falciparum [10,27-30] and P. vivax [32].
However, comparison of in vitro IC50 data among
different Plasmodium species should be cautiously
made and was not the purpose of the present study.
Comparisons of these results, with previous reports
in P. berghei can be also limited since available IC50s
have been obtained through different techniques and
conducted with different strains, hosts, drug dilution pro-
tocols and under diverse parameters of parasitaemia and
haematocrit that can influence the IC50 results [27]; more-
over early in vitro assays described in P. berghei were usu-
ally conducted without synchronization procedures
[3,25,26].
This ELISA method provides a simple procedure to
determine IC50s for anti-malarial drugs in vitro using P.
berghei. Since studies focusing on the identification of
novel drugs often involve the testing of the in vivo effi-
cacy of drug candidates in small animal (rodent) models
of malaria, the availability of simple assays to determine
the in vitro drug-sensitivity of rodent parasites is useful.
Specifically, this assay may help to determine whether a
discrepancy between in vitro P. falciparum drug-
sensitivity and in vivo rodent parasite drug-sensitivity is
the result of intrinsic differences between the two para-
site species or may be due to pharmacokinetic or phar-
macodynamic characteristics of the drug in a live
animal.
Conclusion
In this study, the development of an ELISA-based in vitro
drug assay for P. berghei is reported. This technique is easy
to implement, fast (less than 3 hours), safe (avoids the use
of radioisotopes) and economical (not requiring expensive
equipment such as beta counters, flow cytometers or
luminometers). Although the development of synchronized
infections in mice is time consuming, this is a straightfor-
ward procedure which can be easily implemented in labora-
tories working with murine models. This in vitro assay
represents a robust and useful alternative for the screening
of new anti-malarial compounds in the mouse model of
P. berghei.
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Figure 5 In vitro susceptibility of P. berghei to different anti-malarial drugs. Inhibition of schizont maturation by amodiaquine (squares),
chloroquine (solid circles), artesunate (solid triangles) and quinine (asterisks). Curves derived from micro-test assays are displayed as dashed lines
and open symbols. Each point represents the mean and the standard error of at least three independent assays for PbA and PbAGFP. The IC50
values and standard error of the media are shown in the legend.
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buffered saline; RPMI: Roswell Park Memorial Institute; IV: Intravenously;
OD: Optical density; IC50: Half maximal inhibitory concentration; SD: Standard
deviation; HABA: 4'-hydroxyazobenzene-2-carboxylic acid; DELI: Double-site
enzyme-linked lactate dehydrogenase immunodetection assay; BSA: Bovine
serum albumin; TMB: 3,3',5,5'-tetramethybenzidine; unRBC: Uninfected red
blood cell; cRMPI: Complete RMPI media.
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